View all stories of the same content type.
A comparison of once-daily triple therapy with once-daily dual therapy in the treatment of symptomatic COPD—the IMPACT trial
This supplement has been developed in partnership with GlaxoSmithKline. GlaxoSmithKline suggested the topic, funded production of the supplement, and suggested the author(s); the content has also been checked for factual accuracy to ensure it is fair and balanced, and to ensure its compliance with appropriate regulation. The sponsorship ...